SLC5A2 and atrial fibrillation: A recent retrospective study of patients newly diagnosed with type 2 diabetes and subsequently prescribed SGLT-2 inhibitors showed that the risk for incident atrial fibrillation was significantly lowered, but only among those who achieved a weight loss of of more than 5% [32], implicating the potential to reduce the future prevalence of atrial fibrillation through preventive treatment.